Marius Pharmaceuticals, a company dedicated to developing therapies for testosterone deficiency, has launched a pilot study focusing on the effects of its oral testosterone therapy, KYZATREX (testosterone undecanoate), on male fertility, specifically spermatogenesis. KYZATREX, approved for testosterone replacement therapy in adult males with testosterone deficiency, will be the subject of this pioneering study. The study aims to explore how this oral testosterone…
German pharmaceutical company Bayer recently announced positive results from two Phase III trials of its new menopausal relief drug, elinzanetant. The drug aims to reduce vasomotor symptoms, particularly hot flashes, which are common during menopause. The announcement is significant for Bayer’s pharmaceutical division following a series of challenges in drug development. The clinical trials demonstrated that elinzanetant significantly reduces the frequency and…
You’ve found some of our exclusive Inner Circle Content. This article is only available for our Inner Circle Members. To read on: Sign in to your Inner Circle account to access this content. If you aren’t a member yet and would like to find out more about our Inner Circle program or sign up, click here.
Cosette Pharmaceuticals has acquired Vyleesi, the FDA-approved treatment for Hypoactive Sexual Desire Disorder (HSDD) in premenopausal women, from Palatin Technologies. The transaction, valued at $12 million with an additional $159 million in contingent sales-based milestones, reflects Cosette’s strategic expansion in women’s health despite the drug’s struggling performance in the market. Vyleesi, once anticipated to be a breakthrough akin to “female Viagra,” has…
Organon and Eli Lilly and Company (Lilly) have announced a commercialization agreement that positions Organon as the exclusive distributor and promoter of two migraine medicines, Emgality (galcanezumab) and RAYVOW (lasmiditan), in Europe. Organon, a global healthcare company with a focus on women’s health, will leverage its experience in central nervous system disorders to promote and distribute these medications. Emgality is a humanized…
Astellas Pharma has announced the approval of VEOZA (fezolinetant) by the European Commission for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause. Vasomotor symptoms, which include hot flashes and night sweats, are common during menopause. Studies indicate that more than half of women between the ages of 40 and 64 in Europe experience VMS, with some areas reporting…
A recent survey by Ferring Pharmaceuticals has brought to light the extensive struggles couples in Asia face on their fertility journey. The survey, covering seven Asian markets including India, highlights the long and emotional path to conception, often compounded by a lack of knowledge and emotional support. Long Journey to Parenthood The average duration from the decision to conceive to successful conception…
A recent landmark study announced by Eli Lilly and Company has shown significant long-term benefits of Verzenio (abemaciclib) in treating high-risk early breast cancer (EBC). The findings, unveiled at the 2023 European Society for Medical Oncology (ESMO) Congress, are particularly significant for those at heightened risk of cancer recurrence. The study focused on hormone receptor-positive, HER2-negative, node-positive early breast cancer. Over five…
